ANGPTL4 Antibody: Lipid Lowering Safety & Efficacy – Phase 1/2a Results
- New trials suggest that inhibiting ANGPTL4 with MAR001 effectively and safely lowers both circulating triglycerides and remnant cholesterol.These findings support further investigation into MAR001 as a potential lipid-lowering...
- Additional research and advancement are planned to explore the full potential of MAR001 in managing lipid levels and preventing ASCVD.
MAR001, an ANGPTL4 antibody, demonstrates significant promise in Phase 1/2a trials, safely reducing circulating triglycerides and remnant cholesterol levels. This breakthrough presents a viable path towards lipid-lowering therapy, as reported in the latest findings. These results strongly support further research into MAR001S potential to reduce atherosclerotic cardiovascular disease (ASCVD) risk. Through these pivotal trials, scientists aim to reshape the landscape of heart health treatments. News Directory 3 has the story. With encouraging data in hand, specialists are eager to uncover the full scope of this therapy’s efficacy. Discover what’s next in the quest for improved cardiovascular wellness.
ANGPTL4 Inhibition Shows Promise in Reducing Triglycerides
Updated June 3, 2025
New trials suggest that inhibiting ANGPTL4 with MAR001 effectively and safely lowers both circulating triglycerides and remnant cholesterol.These findings support further investigation into MAR001 as a potential lipid-lowering therapy. The goal is to reduce the risk of atherosclerotic cardiovascular disease (ASCVD).
What’s next
Additional research and advancement are planned to explore the full potential of MAR001 in managing lipid levels and preventing ASCVD.